BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

Search

Almirall SA

Avatud

SektorTervishoid

9.66 1.9

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

9.47

Max

9.71

Põhinäitajad

By Trading Economics

Sissetulek

-430K

-2.1M

Müük

28M

258M

P/E

Sektori keskmine

187.4

57.333

Aktsiakasum

0.04

Dividenditootlus

1.96

Kasumimarginaal

-0.814

Töötajad

2,026

EBITDA

3.9M

45M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+44.82% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.96%

2.63%

Järgmine tulemuste avaldamine

12. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-26M

2B

Eelmine avamishind

7.76

Eelmine sulgemishind

9.66

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Almirall SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. dets 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Almirall SA Prognoos

Hinnasiht

By TipRanks

44.82% tõus

12 kuu keskmine prognoos

Keskmine 13.83 EUR  44.82%

Kõrge 17 EUR

Madal 12 EUR

Põhineb 3 Wall Streeti analüütiku instrumendi Almirall SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

9.42 / 9.65Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Almirall SA

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.